Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SVR & Risk of T2D Among Patients with HCV

J Viral Hepat; ePub 2018 Feb 25; Li, Zhang, et al

Among a large US cohort of patients treated for hepatitis C virus (HCV), patients who achieved sustained virological response (SVR) demonstrated a substantially lower risk for development of type 2 diabetes mellitus (T2D) than patients with treatment failure. This according to a study that examined how response to HCV treatment impacts risk of subsequent T2D. Among HCV patients without a history of T2D or hepatitis B, researchers investigated incidence of T2D from 12 weeks post-HCV-treatment through December 2015. They found:

  • Among 5,127 patients with an average follow-up of 3.7 years, T2D incidence was significantly lower among patients who achieved SVR than among patients with treatment failure (6.2% vs 21.7%).
  • Risk of T2D was higher among African American and Asian American patients vs white patients (adjusted hazard ratio [aHR], 1.82 and 1.75, respectively).
  • Patients with body mass index (BMI) ≥30 and 25-20 demonstrated higher risk than those with BMI <25.
  • Cirrhosis at baseline was also a risk factor.

Citation:

Li J, Zhang T, Gordon SC, et al. Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US. [Published online ahead of print February 25, 2018]. J Viral Hepat. doi:10.1111/jvh.12887.

This Week's Must Reads

CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al

USPSTF: Interventions to Prevent Child Maltreatment, JAMA; 2018 Nov 27; US Preventive Services Task Force

Team-Based Primary Care in Chronically Ill Patients, JAMA Intern Med; ePub 2018 Nov 26; Meyers, et al

Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al

PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al

Must Reads in Hepatitis

Glecaprevir/Pibrentasvir in HCV GT 3 Infection, J Viral Hepat; ePub 2018 Nov 12; Flamm, et al

HCV Therapy Reduces CVD Events in Veterans, Gastroenterology; ePub 2018 Nov 13; Butt, et al

Alcohol Use Disorder in Patients with HCV/HIV , Drug Alcohol Depend; 2018 Oct 30; Frost, et al

Sexually-acquired HCV in MSM Using PrEP, J Infect Dis; ePub 2018 Nov 20; Price, et al

Effective HCV Testing In US Prisons, Am J Prev Med; ePub 2018 Nov 19; Assoumou, et al